Get access

CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma

Authors

  • Céline Pinheiro Ph.D.,

    Corresponding author
    1. Life and Health Sciences Research Institute, Health Sciences School, University of Minho, Braga, Portugal
    2. ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, Portugal
    • Céline Pinheiro, Ph.D., Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710-057 Braga, Portugal
    Search for more papers by this author
  • Adhemar Longatto-Filho Ph.D., PMIAC,

    1. Life and Health Sciences Research Institute, Health Sciences School, University of Minho, Braga, Portugal
    2. ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, Portugal
    3. Laboratory of Medical Investigation 14, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
    Search for more papers by this author
  • Tony R. Soares B.Sc.,

    1. Life and Health Sciences Research Institute, Health Sciences School, University of Minho, Braga, Portugal
    2. ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, Portugal
    Search for more papers by this author
  • Helena Pereira M.Sc.,

    1. Centre of Molecular and Environmental Biology, University of Minho, Braga, Portugal
    Search for more papers by this author
  • Carlos Bedrossian M.D., Ph.D. (HON), FIAC,

    1. Department of Pathology, Rush University Medical College, Chicago, Illinois, USA
    Search for more papers by this author
  • Claire Michael M.D.,

    1. Department of Cytopathology, University of Michigan, Ann Arbor, Michigan, USA
    Search for more papers by this author
  • Fernando C. Schmitt M.D., Ph.D., FIAC,

    1. Medical Faculty, University of Porto, Porto, Portugal
    2. Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal
    Search for more papers by this author
  • Fátima Baltazar Ph.D.

    1. Life and Health Sciences Research Institute, Health Sciences School, University of Minho, Braga, Portugal
    2. ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, Portugal
    Search for more papers by this author

Abstract

Malignant mesothelioma (MM) is a rare form of cancer. Its histopathological diagnosis is very difficult, as it exhibits a number of different appearances that can be misinterpreted as metastatic invasion or atypical hyperplasia. Thus, there is an urgent need to identify adequate markers to distinguish between benign and malignant cells, allowing the implementation of appropriate therapies and, possibly, specific directed therapies. MM, like other tumors, show an increase in glucose uptake, due to high rates of glycolysis, inducing an intracellular overload of acids. In this context, monocarboxylate transporters (MCTs) emerge as important players, by mediating the transmembranar co-transport of lactate with a proton, thereby, regulating pH and allowing continuous glycolysis. Importantly, proper MCT expression and activity depend on its co-expression with a chaperone, CD147, which is associated with poor prognosis in cancer. Twenty-two samples including reactive mesothelial cells, MM, and atypical mesothelial hyperplasias were evaluated for immunoexpression of MCT1, MCT4, and CD147. Expression of these proteins was compared with GLUT1 as a new promising marker for MM. Although MCT isoforms were not differentially expressed in the two types of cytological specimens, CD147, as GLUT1, was almost exclusively expressed in MM. Both MCT1 and MCT4 are not able to discriminate between mesothelial reactive cells and mesothelial malignant cells, while CD147 was able to distinguish these two proliferations. If confirmed, besides being a good marker for identification of MM, CD147 may also be a target for therapeutical strategies in this rare type of tumor. Diagn. Cytopathol. 2012;40:478–483. © 2012 Wiley Periodicals, Inc.

Ancillary